Swedish Orphan Biovitrum AB (publ) — Sponsor Intelligence | 9 EU Trials

Filter these 9 trials by condition, phase, country and more.

Open in Search →

9 Registered trials

2 Recruiting

6 Completed trials

17 Countries active

5 Unique IMPs

100% Results reported

Phase III

Phase II/III

Phase II

Phase IV

Other

Phase III: 2 Phase II/III: 1 Phase II: 1 Phase IV: 4 Other: 1

100%

6 of 6 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

C3 glomerulopathy 1 Thrombotic microangiopathy 1 Immune-complex membranoproliferative glomerulonephritis 1 Haemophagocytic lymphohistiocytosis 1

Top IMPs

EFANESOCTOCOG ALFA 4 EFMOROCTOCOG ALFA 1 EFTRENONACOG ALFA 1 EMAPALUMAB 1 PEGCETACOPLAN 1

All trials

9 total

Real-world study to evaluate how effective and safe Pegcetacoplan is in patients with rare kidney diseases called C3G or IC-MPGN in multiple… Pending

2025-524487-37-00 Phase IV 4 countries PEGCETACOPLAN
Study to provide continued access to treatment for patients completing a previous trial with efanesoctocog alfa Recruiting

2023-506537-29-00 Phase III 10 countries EFANESOCTOCOG ALFA
Long-term study evaluating joint health in people with haemophilia A receiving real-world prophylactic treatment with efanesoctocog alfa Recruiting

2024-517812-31-00 Phase IV 8 countries EFANESOCTOCOG ALFA
A study to investigate the course of synovial hypertrophy in patients with haemophilia A on efanesoctocog alfa prophylaxis Ended

2024-512066-33-00 Phase IV 4 countries EFANESOCTOCOG ALFA
Pharmacokinetic comparison of efanesoctocog alfa vs other EHL-rFVIII products in participants with severe haemophilia A Ended

2023-505801-17-00 4 countries
An 18-month study to assess joint outcomes in patients with haemophilia A or B on prophylaxis with efmoroctocog alfa or eftrenonacog alfa Ended

2022-502921-16-00 Phase IV 10 countries EFMOROCTOCOG ALFA; EFTRENONACOG ALFA
A 24-month study evaluating physical activity and joint health in patients 12 years and older, with severe haemophilia A treated once weekly… Ended

2022-500275-31-00 Phase III 14 countries EFANESOCTOCOG ALFA
A study to evaluate efficacy, safety and tolerability, pharmacokinetics and pharmacodynamics of emapalumab in children and adults with macro… Ended

2024-516153-52-00 Phase II/III 3 countries EMAPALUMAB
Study to evaluate Pegcetacoplan in patients with TA-TMA after hematopoietic stem cell transplantation Ended

2023-510443-37-00 Phase II 4 countries

Showing 1–9 of 9 trials

← All sponsors A–Z